

PATIENT GROUPS

A seat at the pricing table

The actions and advocacy of patient groups to gain access to medicines.

 GREECE



Greece at a glance

58

RESPONDENT
PATIENT GROUPS

43%

REPRESENT INTERESTS
"REGULARLY" OR
"SOMETIMES"

18

GROUPS SHARED
COMMENTARY

REPORT NAVIGATION

Contents

 GREECE

	PAGE
01 Introduction and Methodology	1
02 Country Summary	9
03 Country analyses and results	12
04 Appendix I: Profiles of patient groups	15
05 Appendix II: Patient group respondents that gave permission to be named	16
06 Appendix III: Full list of commentaries – categorised	17

AI-use disclosure

AI was used to support:

- checking data
- data analyses
- product design
- translations

A SEAT AT THE PRICING TABLE

Introduction

Historically, patients and the organisations that represent them were often regarded as little more than passive recipients of healthcare, with limited involvement in shaping the policies, treatment and research priorities that directly affected them. Recently, however, this perception has increasingly been challenged, with patient organisations taking a more active and influential role in shaping healthcare policy at local, regional, national and international levels.

Over recent years, patient organisations have also increasingly advocated for greater involvement in decisions concerning the treatments and care available to the communities they represent, providing invaluable insights into how these decisions directly affect patients and their families. However, relatively little has been known about the extent to which patient organisations are involved in decision-making processes undertaken by regulators, payers and reimbursement bodies.

For the first time, PatientView is seeking to quantify and highlight the extent and impact of patient group involvement in this space, providing greater insight into how patient organisations are contributing to regulatory, reimbursement and healthcare decision-making. This provides policymakers, the private sector and regulators with insight into the activities and perspectives of 2,262 patient groups across disease areas and countries.

While the role of patient groups continues to evolve alongside the wider pharmaceutical and regulatory landscape, one thing is clear: patient groups are increasingly demanding that their voices are heard and meaningfully considered, securing a more prominent and established role in discussions around pricing, and importantly, a seat at the pricing table.

HOW THE RESEARCH WAS CONDUCTED

Methodology

The research presented in “Patient Groups: A Seat at the Pricing Table” sought to establish the extent to which patient groups represent patient interests to drug regulators, payers (including through health technology assessments (HTAs) and medical device assessments) and governmental or policy committees.

Between December 2025 and March 2026, a short survey was circulated to key patient organisations and translated into 22 languages. In total, 2,262 patient groups responded, representing 100 countries and 45 therapy areas.

Both the quantitative and qualitative findings were analysed to identify overarching trends and insights. Where sufficient responses (14 or more respondent patient groups) were received for individual countries or therapy areas, these data were also examined separately.

Among patient groups actively engaging with regulators and payers, responses were analysed against 8 overarching goals and 39 sub-categories, ranging from improving access pathways to upholding patients' rights. In total, 35 countries are examined and 26 therapy areas. (Note that responses can fall in more than one goal or sub-category.)

The following pages present:

1. The overall percentages of the 985 unique respondent patient groups that provided commentary mentioning the types of interaction they have with drug regulators, and the actions and advocacy they undertake to gain access to medicines.
2. A brief explanation of the different types of interactions, actions and advocacy undertaken by patient groups to gain access to medicines.

The research presented on the accompanying website (www.patientview.com) and in this report highlights the findings from this analysis, supported by verbatim responses that capture patient organisations' experiences, priorities and perspectives in their own words.

This report also contains:

1. Overall results
2. Country-specific results
3. Appendix I: Profiles of respondent patient groups
4. Appendix II: Respondent patient groups happy to be named
5. Appendix III: Full set of commentaries from respondent patient groups

For a listing of all respondents to this pricing survey, happy to be named, go to www.patientview.com.

To access country- or therapy-specific reports please write to report@patient-view.com

INTERACTION · PERCENTAGE OF ALL COMMENTS

How patient groups interact with drug regulators


Direct, two-way participation in regulatory, HTA and policy processes.



ACTIONS & ADVOCACY · PERCENTAGE OF ALL COMMENTS

How patient groups get access to medicines

Advocacy, campaigning and activities to secure access to medicines.



How patient organisations engage on securing access to medicines



Interaction



Regulatory partnership

Working with regulatory bodies

Patient organisations engage directly with national medicines regulators and health authorities, submitting contributions, proposals and formal requests. This work establishes them as recognised interlocutors in regulatory processes, and many report actively seeking closer, more formalised relationships with these bodies.

Participate in Health Technology Assessment (HTA) and reimbursement reviews

Groups take part in health technology assessment and reimbursement evaluations, responding to consultations and preparing submissions that accompany reimbursement applications. By feeding into the bodies that appraise new treatments, they help ensure the patient perspective shapes which therapies are ultimately funded. This is the single most frequently reported form of engagement.

Contribute to Marketing Authorisation submissions

Organisations provide input into marketing-authorisation processes for new and orphan medicines, offering opinions to regulators and supporting applications for approval. Their contributions range from scientific-advice committees and fast-track designations to formal position statements backing a product's introduction.

Involvement with clinical guideline-setting bodies

Patient representatives sit on guideline and expert committees, helping to shape clinical standards. Involvement is typically through formal membership of the committees that develop national clinical guidelines and quality standards.

Attend/facilitate meetings with policymakers/regulators

Groups actively request and attend meetings, roundtables and consultative sessions with regulators, ministries and health authorities. Whether convened by invitation or sought proactively, these encounters give patients a direct channel to decision-makers.

With other healthcare advocates

Much engagement happens collectively, through umbrella and federation bodies that advocate on members' behalf. Joint position statements and shared representation amplify the voices of smaller organisations in reimbursement and regulatory forums.



Impacting policy and legislation

Participate in public hearings and consultations

Groups submit formal responses to public consultations and take part in parliamentary hearings, forums and working groups. They use these open processes to convey the patient perspective directly to decision-makers.

Contribute to the drafting of public health legislation

Groups actively help draft and refine health laws, commenting on legislative proposals and, in some cases, sponsoring bills. They contribute technical input and amendments across a range of access, equity and medicines legislation.



Pricing and affordability advocacy

Engage in price-review board negotiations

Groups participate directly in the bodies that set prices and reimbursement terms — completing questionnaires, sitting on advisory councils and joining negotiation roundtables. Their input brings patient priorities into otherwise technical pricing decisions.



Evidence-based patient input

Use patient insights to inform decisions

Organisations systematically gather and convey patient views to inform regulatory, reimbursement and policy decisions — through advisory councils, questionnaires, nominated committee members and formal submissions. This ensures decisions reflect real patient priorities.



Evidence-based patient input *(continued)*

Provide Real-World Evidence (RWE) to regulatory agencies

Groups generate and submit structured real-world evidence and patient-reported outcomes to inform HTA and reimbursement, translating lived experience into policy-relevant data. This articulates treatment burden, unmet needs and value beyond clinical endpoints.

Leverage patient stories and lived-experience narratives

Advocates bring patient and caregiver stories into appraisals, consultations and media to demonstrate the human impact of treatment and access decisions. Lived-experience submissions give qualitative weight to reimbursement cases.

Translate evidence and insights into policy input

Groups convert technical, clinical and scientific evidence into structured recommendations and position papers for decision-makers. Through scientific committees, technical briefs and formal submissions, they recommend which medicines and supplies should be incorporated into health systems.



Diagnosis and medicines delivery

Participate in developing clinical guidelines

Organisations contribute to clinical guideline and care-pathway development through technical working groups and committees. Their involvement helps ensure guidelines reflect patient needs and the realities of everyday care.

Collaborate on clinical trial design

Groups advise on trial design and endpoints, sitting on scientific advisory councils and working with regulators and sponsors. Their input covers issues such as eligibility, trial burden and improving studies for both sponsors and patients.



Institutional governance

Ensure representation within governmental advisory bodies

Patient organisations secure formal seats on government advisory boards, committees and working groups. This embedded representation gives patients standing in ongoing health governance.

Working effectively within multi-stakeholder networks

Groups operate within broad networks linking patients, clinicians, industry, regulators and umbrella bodies. Collaboration across these platforms strengthens their collective influence.

Maintain formal status as public interest or charitable entity

Organisations establish and maintain formal legal standing — public-interest designation, charitable or non-profit registration, or listing on official interest-group registers — to legitimise their advocacy. This status underpins their recognition as social partners to the state.



Actions & Advocacy



Impacting policy and legislation

Influence healthcare policy and legislation

Organisations campaign to shape health policy through petitions, position statements, ministerial engagement and lobbying. Efforts span narrowly targeted reforms through to broad representation of patient interests before ministries and parliaments.

Mobilise parliamentarians and political leaders

Advocates engage directly with parliamentarians, ministers and parliamentary health groups — through hearings, budget submissions and face-to-face meetings — to win political backing. Sustained political mobilisation is repeatedly credited with delivering concrete policy change.

Advocate for patient protection bills and rights

Organisations pursue dedicated legislation to protect patients' rights. Where formal legislative routes stall, some turn to constitutional and legal mechanisms to defend fundamental rights.

Addressing barriers/anomalies in medical care

Advocates identify and challenge specific inequities and gaps in care, such as treatments approved or reimbursed for some patient groups but not others. They press authorities to correct these anomalies and extend access where clinical need is otherwise unmet.



Pricing and affordability advocacy

Advocate for fair medicine pricing

Organisations campaign for affordable, well-reimbursed medicines, raising pricing and out-of-pocket costs with parliaments, insurers and manufacturers. Activity ranges from formal advocacy submissions and reimbursement calls to public and media campaigns highlighting the burden of high drug costs.

Call for reduced selling prices from manufacturers

Some organisations appeal or negotiate directly with pharmaceutical companies to lower prices. Others escalate to pricing alliances and procurement bodies when costs remain out of reach.

Address cost barriers for low-income and vulnerable people

Advocates work to remove financial barriers for those least able to pay, supporting assistance and discount schemes. Efforts focus on low-income patients, welfare recipients and marginalised communities facing prohibitive out-of-pocket costs.

Tracking and monitoring drug pricing/drug shortages

Groups actively monitor prices, availability and shortages, alerting regulators and mobilising their communities when supplies fail. Activity includes civic oversight of pricing compliance, position statements on specific shortages, and engagement with authorities and manufacturers to secure continuity of supply.

Monitoring product substitution

Organisations watch for unilateral substitutions — such as biologic-to-biosimilar switches or altered prescriptions — that may disadvantage patients, and intervene to protect appropriate treatment. Several advocate for legislation requiring explicit prescriber consent before substitution.

Advocating for inclusion of product in reimbursement lists/national formularies

A major focus is getting specific medicines and devices added to reimbursement lists and national formularies. Groups submit applications, complete reimbursement questionnaires and advocate at both regional and national level.

Engaging in awareness campaigns

Organisations run public awareness and prevention campaigns — through media, events and dedicated awareness days — to build understanding and support for their cause. These efforts often accompany calls for better access and encourage public participation in consultations.



Improving access pathways

Facilitate equitable access to medicines/healthcare

This broad, high-volume activity centres on ensuring patients can actually obtain the treatments, tests and services they need. Groups advocate on availability, guide families through access routes, join procurement processes and press for consistent, nationwide provision of appropriate therapy.

Advocate for wider vaccine access

Organisations campaign to expand vaccine access and funding through consumer comments, awareness activity and price-review interventions. Vaccination and equitable access are recurring priorities, often pursued alongside partner networks.

Address disparities in access and management

Advocates highlight and act on regional, socioeconomic and system-level inequities — such as differences in waiting times, or treatments available in one area but not another. They press states and agencies to close these gaps and standardise access.

Improving access to rare/ultra-rare therapies

Given the prohibitive cost of orphan drugs, groups focus specifically on securing access to rare-disease therapies through early-access and compassionate-use programmes and dedicated rare-disease commissions and laws. Cross-border alliances and national rare-disease committees are central to this work.



Evidence-based patient input

Conduct surveys/research to generate data

Organisations run surveys, interviews and research studies to build an evidence base on patient needs, which they share with policymakers and regulators. Instruments range from structured questionnaires to patient-focused research collaborations.



Diagnosis and medicines delivery

Ensure safe and effective medicine use

Advocates engage on medicine safety, quality and appropriate use — raising adverse-event concerns, contributing to pharmacovigilance committees and challenging withdrawals or substandard products. This embeds the patient perspective in safety policy.

Support screening and early detection

Advocates campaign for screening and early-detection programmes, including newborn screening and multi-condition early detection. They provide expertise to funding and regulatory bodies on adding conditions to screening panels.



Upholding patient rights / quality of life

Protecting/improving the patient experience

Advocates defend and improve the patient experience beyond the clinic — across employment, disability support, discrimination and social inclusion — and provide social and legal guidance. They help patients assert their rights and resolve barriers with insurers and authorities.

Support in treatment-related legal actions

Some organisations pursue or support legal action to secure access to treatment, including constitutional and administrative proceedings and litigation for approved therapies. This judicial route is used to compel coverage of high-cost medicines where other channels fall short.

Promoting an emphasis on quality of life

Groups advocate for quality of life and quality of care as ends in themselves — spanning palliative care, accessibility and broader wellbeing. Their input keeps unmet needs and lived quality of life on the agenda alongside clinical and cost considerations.

GREECE

Summary

Of the 58 patient groups responding from Greece, 43% represent patient interests to drug regulators either “regularly” or “sometimes”. 18 gave detail on how they interact with regulators, and on the actions and advocacy they undertake to improve access to medicines.

The most common form of engagement is working alongside other healthcare advocates (33%), followed by participating in public hearings and consultations and using patient insights to inform decisions (both 11%); working directly with regulatory bodies, attending meetings with policymakers and regulators, drawing on patient stories and lived-experience narratives and securing representation within governmental advisory bodies (each 6%). Much of this engagement is channelled through coalitions with other healthcare advocates and umbrella bodies.

“Through written submissions to the Ministry, engagement with local Members of Parliament, direct interpersonal contacts, and the Patient Association of Greece.”

Regional neurodegenerative-conditions patient group, Greece

On actions and advocacy, Greek patient groups concentrate on access and policy and legislation. The leading activities are influencing healthcare policy and legislation and facilitating equitable access to healthcare (both 33%), followed by promoting an emphasis on quality of life (17%); protecting and improving the patient experience (11%); mobilising parliamentarians and political leaders, advocating for fair medicine pricing and supporting screening and early detection (each 6%).

“Where consultation processes are available on the relevant websites, we submit our positions, and we also direct formal requests to the Ministries of Health and Labour [in Greece].”

Regional neurological-conditions patient group, Greece

In summary, Greek patient groups are most active in working alongside other healthcare advocates and, on the access side, influencing healthcare policy and legislation.



Share of patient groups engaging with drug-pricing regulators 'regularly' or 'sometimes'

Total responses = 2,262


Excludes 'don't know' responses and where n < 14 are omitted

SURVEY RESPONSES

Size = No. of respondents
n < 20 read with caution



% High to low



Country analyses and results

 Greece

58 RESPONDENT
PATIENT GROUPS

43% “REGULARLY” OR
“SOMETIMES”
REPRESENT INTERESTS TO
REGULATORS

18 GROUPS SHARED
COMMENTARY

SUMMARY

Under half (43%) of Greek patient groups “Regularly” or “Sometimes” represent patient interests to regulators. These groups appear well connected: one-third engage with other healthcare advocates, while 11% participate in public hearings and consultations. Their advocacy is led, in equal measure, by efforts to facilitate equitable access to medicines and healthcare and to influence health policy and legislation (33% each).

How patient groups in Greece interact with drug regulators

N = 18

GOAL	INTERACTION	%
 Regulatory partnership	With other healthcare advocates	33%
	Working with regulatory bodies	6%
	Attend/facilitate meetings with policymakers/regulators	6%
 Evidence-based patient input	Use patient insights to inform decisions	11%
	Leverage patient stories and lived-experience narratives	6%
 Impacting policy & legislation	Participate in public hearings and consultations	11%
 Institutional governance	Ensure representation within governmental advisory bodies	6%

Pill shade = share of comments — darker is higher

“

The Hellenic League Against Rheumatism (ELEANA) regularly represents patient interests to national and European regulators through formal consultations, written submissions, participation in policy dialogues, and involvement in European patient advocacy platforms (e.g., EULAR [European Alliance of Associations for Rheumatology] PARE [People with Arthritis/Rheumatism in Europe], EPF [European Patients' Forum], GAfPA [Global Alliance for Patient Access]).

**ATTEND/FACILITATE MEETINGS WITH
POLICYMAKERS/REGULATORS**

National rheumatic-diseases patient group, Greece

“

AGORA Federation represents patient perspectives through EU-level policy dialogues and consultations, and via participation in European patient advocacy platforms. We contribute input on access, reimbursement, unmet needs, and quality of life across rheumatic and musculoskeletal diseases from a cross-country (Southern Europe) perspective.

**PARTICIPATE IN PUBLIC HEARINGS AND
CONSULTATIONS**

**International rheumatic-diseases patient group,
Greece**

 Greece

How patient groups in Greece get access to medicines

N = 18

GOAL	ACTIONS & ADVOCACY	%
 Diagnosis & medicines delivery	Support screening and early detection	6%
 Impacting policy & legislation	Influence healthcare policy and legislation	33%
	Mobilise parliamentarians and political leaders	6%
 Pricing & affordability	Advocate for fair medicine pricing	6%
 Improving access pathways	Facilitate equitable access to medicines/healthcare	33%
 Patient rights & wellbeing	Promoting an emphasis on quality of life	17%
	Protecting/improving the patient experience	11%

Pill shade = share of comments – darker is higher

“

As a member of secondary and tertiary federations representing persons with disabilities and persons with multiple sclerosis, and through direct engagement with public authorities, we advocate on behalf of our members by submitting requests for access to therapeutic treatments and therapies, as well as for the protection of their rights vis-à-vis the state.

FACILITATE EQUITABLE ACCESS TO
MEDICINES/HEALTHCARE

**Regional neurological-conditions patient group,
Greece**

“

Through written submissions to the Ministry, engagement with local Members of Parliament, direct interpersonal contacts, and the Patient Association of Greece.

INFLUENCE HEALTHCARE POLICY AND LEGISLATION

**Regional neurodegenerative-conditions patient
group, Greece**

Appendices

Appendix I: Profiles of patient groups

Appendix II: Patient group respondents that gave permission to be named

Appendix III: Full list of commentaries – categorised

APPENDIX • PATIENT GROUP PROFILES

Profiles of respondent patient groups in Greece

58

RESPONDENT PATIENT GROUPS

277,300


PATIENTS REACHED

32

SPECIALITY AREAS


GEOGRAPHIC REACH

Percentage of total respondent patient groups in Greece



SPECIALITIES

Percentage of total respondent patient groups in Greece

n = 58 respondent patient groups • 32 speciality areas represented

APPENDIX II • RESPONDENTS THAT GAVE PERMISSION TO BE NAMED

Respondent patient groups in Greece that gave permission to be named

Patient groups that consented to be named, listed alphabetically.
Where a group provided a website, its name links to it.

Agora Platform - Federation of Southern European organizations of people with RMDs
 FairLife LCC - Φροντίδα και Πρόληψη για τον καρκίνο του πνεύμονα
 Rare Alliance Greece 95
 Αρμονία - Σύλλογος Φίλοι Ασθενών με Πρωτοπαθή Ανοσοανεπάρκεια και Κλινικής Ανοσολογίας
 Ε.Ε.Α.Σ.Κ.Π. - Ελληνική Ένωση για την Αντιμετώπιση της Σκλήρυνσης Κατά Πλάκας Δυτικής Ελλάδος
 Ε.Σ.Α.Ε. - Ένωση Σπανίων Ασθενών Ελλάδος
 Ελληνική Εταιρεία για την Σκλήρυνση κατά Πλάκας
 Ελληνική Εταιρία Προστασίας Αυτιστικών Ατόμων (Ε.Ε.Π.Α.Α.)
 Ελληνικός Σύλλογος για την Αταξία του Φρίντριχ (HEFAA)
 Επιδέρμια - Πανελλήνιος Σύλλογος Ασθενών
 ΙΦΝΕ Αχαΐας - Σωματείο Ατόμων με Νόσο του Crohn και Ελκώδη Κολίτιδα Αχαΐας
 Πανελλήνιος Σύλλογος Ατόμων και Γονέων Παιδών με Συγγενείς Ορθοπρωκτικές Ανωμαλίες (SPANIOS)
 Πανελλήνιος Σύλλογος Γυναικών με Καρκίνο Μαστού «Άλμα Ζωής»
 Πανελλήνιος Σύλλογος Διαφυητικής Ιδρωταδενίτιδας - Α λ κ ή
 Πανελλήνιος Σύνδεσμος Νεφροπαθών (Π.Σ.Ν.)
 Πανελλήνιος Σύνδεσμος Πασχόντων από Καρδιοπάθειες
 Πανελλήνιος Σύνδεσμος Πασχόντων από Καρδιοπάθειες (Πανελληνιος Συνδεσμος Π.Α.Κ.)
 ΠΟΑμΣΚΠ - Πανελλήνια Ομοσπονδία Ατόμων με Σκλήρυνση Κατά Πλάκας
 ΡευΜΑζην - Πανελλήνια Ομοσπονδία Συλλόγων Ασθενών, γονέων, κηδεμόνων και φίλων παιδιών με ρευματικά νοσήματα
 ΣΥ.Π.ΠΑ.ΔΡΕ.ΜΙ.Α. - Πανελλήνιος Σύλλογος Προστασίας Πασχόντων από Δρεπανοκυτταρική και Μικροδρεπανοκυτταρική Αναμία
 Σύλλογος ατόμων με σκλήρυνση κατά πλάκας Εορδαίας
 Σύλλογος Καρκινοπαθών, Εθελοντών, Φίλων, Ιατρών «Κ.Ε.Φ.Ι.»
 Σύλλογος Ρευματοπαθών Κρήτης
 Σύλλογος Σκελετικής Υγείας Πεταλούδα
 Σωματείο Ατόμων με Σκλήρυνση Κατά Πλάκας Χίου
 Σωματείο Υποστήριξης Ασθενών με Ψωρίαση και Ψωριασική Αρθρίθεια «Καλυψώ»

GREECE

What patient groups told us – commentaries by category (34 categorised entries)

Interaction with drug regulators

INTERACTION

✓ Regulatory partnership

Working with regulatory bodies

“Written submissions and meetings with stakeholder organisations.”

«Γραπτές παρεμβάσεις, συναντήσεις με φορείς.»

National cancer patient group, Greece

Attend/facilitate meetings with policymakers/regulators

“The Hellenic League Against Rheumatism (ELEANA) regularly represents patient interests to national and European regulators through formal consultations, written submissions, participation in policy dialogues, and involvement in European patient advocacy platforms (e.g., EULAR [European Alliance of Associations for Rheumatology] PARE [People with Arthritis/Rheumatism in Europe], EPF [European Patients’ Forum], GAfPA [Global Alliance for Patient Access]).”

National rheumatic-diseases patient group, Greece

With other healthcare advocates

“As a member of secondary and tertiary federations representing persons with disabilities and persons with multiple sclerosis, and through our direct engagement with the state, we advocate on behalf of our members.”

«Ως μέλος δευτεροβάθμιων και τριτοβάθμιων ομοσπονδιών ατόμων με Αναπηρία και ατόμων με Πολλαπλή Σκλήρυνση αλλά και με ενέργειες απευθυνόμενοι στην πολιτεία, υποστηρίζουμε τα μέλη μας με αιτήματα για παροχή θεραπευτικών αγωγών και θεραπειών αλλά και των δικαιωμάτων τους έναντι της πολιτείας κ.λπ.»

Regional neurological-conditions patient group, Greece

“Submits proposals to the collective “umbrella” body.”

«Υποβάλλει προτάσεις στο συλλογικό όργανο «ομπρέλα».»

National rare-disease patient group, Greece

“Through written submissions to the Ministry, engagement with local Members of Parliament, direct interpersonal contacts, and the Patient Association of Greece.”

«Μέσω εγγράφων προς το Υπουργείο, τοπικούς βουλευτές, διαπροσωπικών επαφών και της Ένωσης Ασθενών Ελλάδος.»

Regional neurodegenerative-conditions patient group, Greece

“Through ΕΛΟΔΙ [Ελληνική Ομοσπονδία για τον Διαβήτη – Hellenic Federation for Diabetes].”

«Μέσω της ΕΛΟΔΙ.»

Regional diabetes patient group, Greece

“The Hellenic League Against Rheumatism (ELEANA) regularly represents patient interests to national and European regulators through formal consultations, written submissions, participation in policy dialogues, and involvement in European patient advocacy platforms (e.g., EULAR [European Alliance of Associations for Rheumatology] PARE [People with Arthritis/Rheumatism in Europe], EPF [European Patients’ Forum], GAfPA [Global Alliance for Patient Access]).”

National rheumatic-diseases patient group, Greece

“AGORA Federation represents patient perspectives through EU-level policy dialogues and consultations, and via participation in European patient advocacy platforms. We contribute input on access, reimbursement, unmet needs, and quality of life across rheumatic and musculoskeletal diseases from a cross-country (Southern Europe) perspective.”

International rheumatic-diseases patient group, Greece

Evidence-based patient input

Use patient insights to inform decisions

“... The Hellenic League Against Rheumatism (ELEANA) contributes patient perspectives on access to treatments, reimbursement, unmet needs, and quality of life in autoimmune rheumatic diseases, both at national level (Greece) and at EU level.”

National rheumatic-diseases patient group, Greece

“AGORA Federation represents patient perspectives through EU-level policy dialogues and consultations, and via participation in European patient advocacy platforms. We contribute input on access, reimbursement, unmet needs, and quality of life across rheumatic and musculoskeletal diseases from a cross-country (Southern Europe) perspective.”

International rheumatic-diseases patient group, Greece

Leverage patient stories and lived-experience narratives

“Patient interests only [to drug regulatory authorities].”

«Μόνο συμφέροντα των ασθενών.»

Regional immune-disorders patient group, Greece

Impacting policy and legislation

Participate in public hearings and consultations

“Where consultation processes are available on the relevant websites, we submit our positions, and we also direct formal requests to the Ministries of Health and Labour [in Greece].”

«Όπου υπάρχει διαβούλευση στις σχετικές ιστοσελίδες, εκφράζουμε την άποψή μας, καθώς και με ανάλογα αιτήματα στα Υπουργεία Υγείας και Εργασίας.»

Regional neurological-conditions patient group, Greece

“AGORA Federation represents patient perspectives through EU-level policy dialogues and consultations, and via participation in European patient advocacy platforms. We contribute input on access, reimbursement, unmet needs, and quality of life across rheumatic and musculoskeletal diseases from a cross-country (Southern Europe) perspective.”

International rheumatic-diseases patient group, Greece

Institutional governance

Ensure representation within governmental advisory bodies

“Participation in Ministry committees addressing chronic disease patients, medicinal products, patient rights.”

«Σε επιτροπές Υπουργείων για χρόνιους πάσχοντες, το φάρμακο, τα δικαιώματα των ασθενών και.»

National patient group, Greece

Actions & advocacy to access medicines

ACTIONS & ADVOCACY

Diagnosis & medicines delivery

Support screening and early detection

“Advocacy for access to medicines, diagnostic tests, and related services.”

«Διεκδικήσεις για φάρμακο, εξετάσεις κλπ.»

National rare-disease patient group, Greece

Impacting policy and legislation

Influence healthcare policy and legislation

“National Strategic Plan for CVD [Cardiovascular Disease].”

«NATIONAL STRATEGIC PLAN FOR CVD»

National cardiovascular patient group, Greece

“Advocacy for patient pharmacotherapy at the Ministry of Health.”

«Παρέμβαση για φαρμακευτική αγωγή ασθενών στο Υπουργείο Υγείας.»

National bone-conditions patient group, Greece

“As a member of secondary and tertiary federations representing persons with disabilities and persons with Multiple Sclerosis, and through direct engagement with public authorities, we advocate on behalf of our members by submitting requests for access to therapeutic treatments and therapies, as well as for the protection of their rights vis-à-vis the state.”

«Ως μέλος δευτεροβάθμιων και τριτοβάθμιων ομοσπονδιών ατόμων με Αναπηρία και ατόμων με Πολλαπλή Σκλήρυνση αλλά και με ενέργειες απευθυνόμενοι στην πολιτεία, υποστηρίζουμε τα μέλη μας με αιτήματα για παροχή θεραπευτικών αγωγών και θεραπειών αλλά και των δικαιωμάτων τους έναντι της πολιτείας κ.λπ.»

Regional neurological-conditions patient group, Greece

“We engage in lobbying activities to advance and protect the interests of patients.”

«Κάνουμε λομπινγκ για να στηρίξουμε τα συμφέροντα των ασθενών.»

National carers patient group, Greece

“Where consultation processes are available on the relevant websites, we submit our positions, and we also direct formal requests to the Ministries of Health and Labour [in Greece].”

«Όπου υπάρχει διαβούλευση στις σχετικές ιστοσελίδες, εκφράζουμε την άποψή μας, καθώς και με ανάλογα αιτήματα στα Υπουργεία Υγείας και Εργασίας.»

Regional neurological-conditions patient group, Greece

“Through written submissions to the Ministry, engagement with local Members of Parliament, direct interpersonal contacts, and the Patient Association of Greece.”

«Μέσω εγγράφων προς το Υπουργείο, τοπικούς βουλευτές, διαπροσωπικών επαφών και της Ένωσης Ασθενών Ελλάδος.»

Regional neurodegenerative-conditions patient group, Greece

Mobilise parliamentarians and political leaders

“Through written submissions to the Ministry, engagement with local Members of Parliament, direct interpersonal contacts, and the Patient Association of Greece.”

«Μέσω εγγράφων προς το Υπουργείο, τοπικούς βουλευτές, διαπροσωπικών επαφών και της Ένωσης Ασθενών Ελλάδος.»

Regional neurodegenerative-conditions patient group, Greece

Pricing and affordability

Advocate for fair medicine pricing

“AGORA Federation represents patient perspectives through EU-level policy dialogues and consultations, and via participation in European patient advocacy platforms. We contribute input on access, reimbursement, unmet needs, and quality of life across rheumatic and musculoskeletal diseases from a cross-country (Southern Europe) perspective.”

International rheumatic-diseases patient group, Greece

Improving access pathways

Facilitate equitable access to medicines/healthcare

“Advocacy for patient pharmacotherapy at the Ministry of Health.”

«Παρέμβαση για φαρμακευτική αγωγή ασθενών στο Υπουργείο Υγείας.»

National bone-conditions patient group, Greece

“Advocacy for access to medicines, diagnostic tests, and related services.”

«Διεκδικήσεις για φάρμακο, εξετάσεις κλπ.»

National rare-disease patient group, Greece

“As a member of secondary and tertiary federations representing persons with disabilities and persons with multiple sclerosis, and through direct engagement with public authorities, we advocate on behalf of our members by submitting requests for access to therapeutic treatments and therapies, as well as for the protection of their rights vis-à-vis the state.”

«Ως μέλος δευτεροβάθμιων και τριτοβάθμιων ομοσπονδιών ατόμων με Αναπηρία και ατόμων με Πολλαπλή Σκλήρυνση αλλά και με ενέργειες απευθυνόμενοι στην πολιτεία, υποστηρίζουμε τα μέλη μας με αιτήματα για παροχή θεραπευτικών αγωγών και θεραπειών αλλά και των δικαιωμάτων τους έναντι της πολιτείας κ.λπ.»

Regional neurological-conditions patient group, Greece

“Issues relating to employment, accessibility, health inequalities, and the management of treatment options.”

«Εργασιακά θέματα, προσβασιμότητας, ανισοτήτων, διαχείρισης επιλογών.»

National cancer patient group, Greece

“... The Hellenic League Against Rheumatism (ELEANA) contributes patient perspectives on access to treatments, reimbursement, unmet needs, and quality of life in autoimmune rheumatic diseases, both at national level (Greece) and at EU level.”

National rheumatic-diseases patient group, Greece

“AGORA Federation represents patient perspectives through EU-level policy dialogues and consultations, and via participation in European patient advocacy platforms. We contribute input on access, reimbursement, unmet needs, and quality of life across rheumatic and musculoskeletal diseases from a cross-country (Southern Europe) perspective.”

International rheumatic-diseases patient group, Greece

♥ Patient rights & wellbeing

Protecting/improving the patient experience

“As a member of secondary and tertiary federations representing persons with disabilities and persons with Multiple Sclerosis, and through direct engagement with public authorities, we advocate on behalf of our members by submitting requests for access to therapeutic treatments and therapies, as well as for the protection of their rights vis-à-vis the state.”

«Ως μέλος δευτεροβάθμιων και τριτοβάθμιων ομοσπονδιών ατόμων με Αναπηρία και ατόμων με Πολλαπλή Σκλήρυνση αλλά και με ενέργειες απευθυνόμενοι στην πολιτεία, υποστηρίζουμε τα μέλη μας με αιτήματα για παροχή θεραπευτικών αγωγών και θεραπειών αλλά και των δικαιωμάτων τους έναντι της πολιτείας κ.λπ.»

Regional neurological-conditions patient group, Greece

“Issues relating to employment, accessibility, health inequalities, and the management of treatment options.”

«Εργασιακά θέματα, προσβασιμότητας, ανισοτήτων, διαχείρισης επιλογών.»

National cancer patient group, Greece

Promoting an emphasis on quality of life

“Advocating for quality of care and quality of life for patients.”

«ΔΙΕΚΔΗΚΗΣΗ ΠΟΙΟΤΗΤΑΣ ΦΡΟΝΤΙΔΑΣ ΚΑΙ ΖΩΗΣ ΑΣΘΕΝΩΝ.»

National cancer patient group, Greece

“Issues relating to employment, accessibility, health inequalities, and the management of treatment options.”

«Εργασιακά θέματα, προσβασιμότητας, ανισοτήτων, διαχείρισης επιλογών.»

National cancer patient group, Greece

“AGORA Federation represents patient perspectives through EU-level policy dialogues and consultations, and via participation in European patient advocacy platforms. We contribute input on access, reimbursement, unmet needs, and quality of life across rheumatic and musculoskeletal diseases from a cross-country (Southern Europe) perspective.”

International rheumatic-diseases patient group, Greece

Contact details

PatientView Ltd

Registered office: One Fleet Place, London,
EC4M 7WS, UK

Tel: +44-(0)1547-520-965

Email: report@patient-view.com

Registered in England, Number: 3944382

Data protection registration number: Z7133076

VAT registration number: GB-760-985-885

Copyright© 2026 PatientView Ltd

ALL RIGHTS RESERVED

THIS BOOKLET IS THE PROPERTY OF
PATIENTVIEW™, AND NO PART MAY BE
REPRODUCED WITHOUT PERMISSION, OR
PASSED ON TO ANY THIRD PARTY, WITHOUT
THE PERMISSION OF PATIENTVIEW